EGFR and non-small cell lung carcinoma: In this respect, a cetuximab-based EGFR degrader, was able to reduce proliferation and induce apoptosis in EGFR-mutated NSCLC cell lines [135], suggesting that antibody-based PROTACs might potentially represent an alternative tool for fighting osimertinib resistance.